SEC Form 4 · accession 0001209191-15-028969
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amit Sachdev
Officer — EVP, Policy, Access & Value
Period of report
Mar 20, 2015
Accepted (ET)
Mar 24, 2015 · 6:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 20, 2015 | M | 1,468 | $48.74 | A | 91,452 | D | |
| Common Stock | Mar 20, 2015 | M | 10,532 | $45.11 | A | 101,984 | D | |
| Common Stock | Mar 20, 2015 | S | 12,000 | $135.08 | D | 89,984 | D | |
| Common StockF2,F3 | Mar 23, 2015 | S | 300 | $122.78 | D | 89,684 | D | |
| Common StockF3,F4 | Mar 23, 2015 | S | 1,783 | $125.07 | D | 87,901 | D | |
| Common StockF3,F5 | Mar 23, 2015 | S | 2,200 | $125.93 | D | 85,701 | D | |
| Common StockF3,F6 | Mar 23, 2015 | S | 600 | $127.16 | D | 85,101 | D | |
| Common StockF3,F7 | Mar 23, 2015 | S | 200 | $127.90 | D | 84,901 | D | |
| Common Stock | holding | — | — | — | 882 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F8 | $48.74 | Mar 20, 2015 | M | 1,468 | D | — | Jul 24, 2022 | Common Stock | 1,468 | 29,032 | D |
| Stock Option (right to buy)F9 | $45.11 | Mar 20, 2015 | M | 10,532 | D | — | Feb 4, 2023 | Common Stock | 10,532 | 28,593 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $122.78 (range $122.46 to $123.24).
- F3Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $125.07 (range $124.56 to $125.51).
- F5Open market sales reported on this line occurred at a weighted average price of $125.93 (range $125.61 to $126.50).
- F6Open market sales reported on this line occurred at a weighted average price of $127.16 (range $126.74 to $127.72).
- F7Open market sales reported on this line occurred at a weighted average price of $127.90 (range $127.87 to $127.92).
- F8The option vests in 16 quarterly installments from 07/25/2012.
- F9The option vests in 16 quarterly installments from 02/05/2013.